Trial Outcomes & Findings for Online Treatment of Cognitive Impairment and Insomnia in Cancer Survivors (NCT NCT04026048)
NCT ID: NCT04026048
Last Updated: 2025-04-06
Results Overview
The FACT-Cog was used to measure perceived cognitive impairment (PCI). It is a 37-item questionnaire with four cognitive subscales: perceived cognitive impairments, impact on quality of life, comments from others, and perceived cognitive abilities. Responses range from 0, ''never,'' to 4, ''several times a day,'' in the previous 7 days and negatively worded items are reverse scored to create subscale scores. Scores on the PCI subscale can range from 0 to 72 points, with a higher score indicative of better self-reported cognitive functioning and quality of life. A change of 5.9-points has been established as clinically meaningful change on the FACT-Cog PCI subscale
COMPLETED
NA
132 participants
Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up
2025-04-06
Participant Flow
Participant milestones
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
Pre-treatment to Treatment Completion
STARTED
|
63
|
69
|
|
Pre-treatment to Treatment Completion
COMPLETED
|
58
|
63
|
|
Pre-treatment to Treatment Completion
NOT COMPLETED
|
5
|
6
|
|
3 Month Follow-up
STARTED
|
58
|
63
|
|
3 Month Follow-up
COMPLETED
|
55
|
60
|
|
3 Month Follow-up
NOT COMPLETED
|
3
|
3
|
|
6 Month Follow-up
STARTED
|
55
|
60
|
|
6 Month Follow-up
COMPLETED
|
53
|
59
|
|
6 Month Follow-up
NOT COMPLETED
|
2
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Online Treatment of Cognitive Impairment and Insomnia in Cancer Survivors
Baseline characteristics by cohort
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Total
n=132 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
59.21 years
STANDARD_DEVIATION 11.93 • n=99 Participants
|
61.25 years
STANDARD_DEVIATION 10.60 • n=107 Participants
|
60.28 years
STANDARD_DEVIATION 11.26 • n=206 Participants
|
|
Sex: Female, Male
Female
|
50 Participants
n=99 Participants
|
52 Participants
n=107 Participants
|
102 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
13 Participants
n=99 Participants
|
17 Participants
n=107 Participants
|
30 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
White
|
57 Participants
n=99 Participants
|
65 Participants
n=107 Participants
|
122 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
BIPOC
|
6 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
10 Participants
n=206 Participants
|
|
Region of Enrollment
Canada
|
63 participants
n=99 Participants
|
69 participants
n=107 Participants
|
132 participants
n=206 Participants
|
|
Years of education
High school (≤11 years)
|
4 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Years of education
College (12-14 years)
|
18 Participants
n=99 Participants
|
24 Participants
n=107 Participants
|
42 Participants
n=206 Participants
|
|
Years of education
Postsecondary (≥15 years)
|
41 Participants
n=99 Participants
|
43 Participants
n=107 Participants
|
84 Participants
n=206 Participants
|
|
Employment status
Not working/retired
|
36 Participants
n=99 Participants
|
48 Participants
n=107 Participants
|
84 Participants
n=206 Participants
|
|
Employment status
Working (part or full-time)
|
27 Participants
n=99 Participants
|
21 Participants
n=107 Participants
|
48 Participants
n=206 Participants
|
|
Cancer type
Breast
|
25 Participants
n=99 Participants
|
29 Participants
n=107 Participants
|
54 Participants
n=206 Participants
|
|
Cancer type
Prostate and male genitourinary
|
2 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Cancer type
Female genitourinary
|
6 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
11 Participants
n=206 Participants
|
|
Cancer type
GI tract
|
2 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Cancer type
Hematologic
|
11 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
16 Participants
n=206 Participants
|
|
Cancer type
Skin
|
2 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Cancer type
Other
|
4 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Cancer type
Multiple types
|
11 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
23 Participants
n=206 Participants
|
|
Time since cancer diagnosis (years)
<2
|
7 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
14 Participants
n=206 Participants
|
|
Time since cancer diagnosis (years)
2-4
|
11 Participants
n=99 Participants
|
21 Participants
n=107 Participants
|
32 Participants
n=206 Participants
|
|
Time since cancer diagnosis (years)
5-9
|
17 Participants
n=99 Participants
|
14 Participants
n=107 Participants
|
31 Participants
n=206 Participants
|
|
Time since cancer diagnosis (years)
≥10
|
28 Participants
n=99 Participants
|
26 Participants
n=107 Participants
|
54 Participants
n=206 Participants
|
|
Cancer stage
Stage 0/in situ
|
1 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Cancer stage
Stage I
|
12 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
27 Participants
n=206 Participants
|
|
Cancer stage
Stage II
|
13 Participants
n=99 Participants
|
10 Participants
n=107 Participants
|
23 Participants
n=206 Participants
|
|
Cancer stage
Stage III
|
15 Participants
n=99 Participants
|
13 Participants
n=107 Participants
|
28 Participants
n=206 Participants
|
|
Cancer stage
Stage IV
|
2 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Cancer stage
Unknown/not applicable
|
20 Participants
n=99 Participants
|
23 Participants
n=107 Participants
|
43 Participants
n=206 Participants
|
|
Cancer treatments received
Surgery
|
52 Participants
n=99 Participants
|
65 Participants
n=107 Participants
|
117 Participants
n=206 Participants
|
|
Cancer treatments received
Chemotherapy
|
46 Participants
n=99 Participants
|
35 Participants
n=107 Participants
|
81 Participants
n=206 Participants
|
|
Cancer treatments received
Radiation
|
38 Participants
n=99 Participants
|
38 Participants
n=107 Participants
|
76 Participants
n=206 Participants
|
|
Cancer treatments received
Hormone therapy
|
13 Participants
n=99 Participants
|
29 Participants
n=107 Participants
|
42 Participants
n=206 Participants
|
|
Cancer treatments received
Other
|
4 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Time since insomnia began (months)
|
99.19 months
STANDARD_DEVIATION 71.17 • n=99 Participants
|
88.56 months
STANDARD_DEVIATION 79.23 • n=107 Participants
|
93.63 months
STANDARD_DEVIATION 75.39 • n=206 Participants
|
|
Baseline insomnia score
|
17.27 units on a scale
STANDARD_DEVIATION 3.53 • n=99 Participants
|
17.88 units on a scale
STANDARD_DEVIATION 3.83 • n=107 Participants
|
17.59 units on a scale
STANDARD_DEVIATION 3.69 • n=206 Participants
|
|
Baseline perceived cognitive impairment score
|
39.40 units on a scale
STANDARD_DEVIATION 12.32 • n=99 Participants
|
38.80 units on a scale
STANDARD_DEVIATION 13.86 • n=107 Participants
|
39.1 units on a scale
STANDARD_DEVIATION 13.10 • n=206 Participants
|
PRIMARY outcome
Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
The FACT-Cog was used to measure perceived cognitive impairment (PCI). It is a 37-item questionnaire with four cognitive subscales: perceived cognitive impairments, impact on quality of life, comments from others, and perceived cognitive abilities. Responses range from 0, ''never,'' to 4, ''several times a day,'' in the previous 7 days and negatively worded items are reverse scored to create subscale scores. Scores on the PCI subscale can range from 0 to 72 points, with a higher score indicative of better self-reported cognitive functioning and quality of life. A change of 5.9-points has been established as clinically meaningful change on the FACT-Cog PCI subscale
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
Baseline
|
39.39 score on a scale
Standard Deviation 12.32
|
38.79 score on a scale
Standard Deviation 13.85
|
|
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
4 weeks
|
48.28 score on a scale
Standard Deviation 11.89
|
44.71 score on a scale
Standard Deviation 13.84
|
|
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
8 weeks
|
53.44 score on a scale
Standard Deviation 12.01
|
43.00 score on a scale
Standard Deviation 12.89
|
|
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
3 months follow-up
|
53.16 score on a scale
Standard Deviation 11.37
|
46.21 score on a scale
Standard Deviation 19.64
|
|
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
6 months follow-up
|
52.47 score on a scale
Standard Deviation 12.89
|
51.46 score on a scale
Standard Deviation 14.10
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
The ISI is designed to specifically assess the severity of insomnia symptoms, the impact on daytime functioning, and the amount of associated distress. The ISI has 7 questions, which are summed to compute a total score. The range of the ISI is 0-28 with the higher the value, the more severe the insomnia severity.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
The Insomnia Severity Index (ISI)
Basline
|
17.27 score on Insomnai Severity Index
Standard Deviation 3.53
|
15.06 score on Insomnai Severity Index
Standard Deviation 4.57
|
|
The Insomnia Severity Index (ISI)
4 weeks
|
9.67 score on Insomnai Severity Index
Standard Deviation 4.01
|
9.77 score on Insomnai Severity Index
Standard Deviation 4.81
|
|
The Insomnia Severity Index (ISI)
8 weeks
|
6.03 score on Insomnai Severity Index
Standard Deviation 3.90
|
6.34 score on Insomnai Severity Index
Standard Deviation 4.30
|
|
The Insomnia Severity Index (ISI)
3 months follow-up
|
7.11 score on Insomnai Severity Index
Standard Deviation 4.84
|
6.37 score on Insomnai Severity Index
Standard Deviation 4.60
|
|
The Insomnia Severity Index (ISI)
6 months follow-up
|
7.94 score on Insomnai Severity Index
Standard Deviation 5.60
|
6.28 score on Insomnai Severity Index
Standard Deviation 4.23
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.
Sleep efficiency is the percentage of time spent asleep while in bed. It is calculated by dividing the amount of time spent asleep (in minutes) by the total amount of time in bed (in minutes). The unit of measure is a percentage and is averaged over the whole week for the total sleep efficiency score.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
4 weeks
|
87.18 percentage of sleep efficiency
Standard Deviation 8.17
|
88.10 percentage of sleep efficiency
Standard Deviation 6.24
|
|
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
Baseline
|
73.22 percentage of sleep efficiency
Standard Deviation 12.45
|
74.03 percentage of sleep efficiency
Standard Deviation 13.58
|
|
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
8 weeks
|
89.63 percentage of sleep efficiency
Standard Deviation 7.10
|
89.33 percentage of sleep efficiency
Standard Deviation 6.41
|
|
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
3 month follow-up
|
88.58 percentage of sleep efficiency
Standard Deviation 8.02
|
87.22 percentage of sleep efficiency
Standard Deviation 7.62
|
|
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
6 month follow-up
|
88.52 percentage of sleep efficiency
Standard Deviation 7.88
|
87.83 percentage of sleep efficiency
Standard Deviation 6.81
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.
The sleep diary will be used to calculate sleep-onset latency, which is the length of time that it takes to accomplish the transition from full wakefulness to sleep. The unit of measure is minutes and is averaged over the whole week for the total sleep onset latency score.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
Baseline
|
40.56 minutes
Standard Deviation 32.40
|
41.48 minutes
Standard Deviation 34.22
|
|
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
4 weeks
|
16.68 minutes
Standard Deviation 15.73
|
16.98 minutes
Standard Deviation 13.43
|
|
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
8 weeks
|
12.68 minutes
Standard Deviation 8.98
|
15.41 minutes
Standard Deviation 11.7
|
|
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
3 month follow-up
|
16.70 minutes
Standard Deviation 18.44
|
21.43 minutes
Standard Deviation 16.04
|
|
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
6 month follow-up
|
14.71 minutes
Standard Deviation 10.41
|
22.26 minutes
Standard Deviation 20.24
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.
The sleep diary will be used to calculate wake after sleep onset, which refers to periods of wakefulness occurring after defined sleep onset. The score is reported in minutes and is averaged over the whole week for the total wake after sleep onset.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
6 month follow-up
|
21.46 minutes
Standard Deviation 20.24
|
21.85 minutes
Standard Deviation 20.34
|
|
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
Baseline
|
63.29 minutes
Standard Deviation 41.99
|
50.80 minutes
Standard Deviation 34.14
|
|
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
4 weeks
|
23.32 minutes
Standard Deviation 17.30
|
19.90 minutes
Standard Deviation 14.87
|
|
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
8 weeks
|
21.84 minutes
Standard Deviation 19.80
|
20.06 minutes
Standard Deviation 18.95
|
|
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
3 month follow-up
|
20.06 minutes
Standard Deviation 20.46
|
22.87 minutes
Standard Deviation 19.86
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.
The sleep diary will be used to calculate total sleep time. The score is reported in minutes and is averaged over the whole week for the total sleep time.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
Baseline
|
370.06 minutes
Standard Deviation 67.72
|
378.41 minutes
Standard Deviation 81.09
|
|
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
4 weeks
|
358.77 minutes
Standard Deviation 64.05
|
376.08 minutes
Standard Deviation 59.71
|
|
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
8 weeks
|
392.14 minutes
Standard Deviation 52.52
|
406.40 minutes
Standard Deviation 57.11
|
|
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
3 month follow-up
|
412.06 minutes
Standard Deviation 68.69
|
418.81 minutes
Standard Deviation 62.12
|
|
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
6 month follow-up
|
401.42 minutes
Standard Deviation 84.67
|
429.24 minutes
Standard Deviation 56.60
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
Anxiety and Depression will be measured using the HADS, which is a 14-item, self-rated instrument for anxiety (7 items) and depression (7 items) symptoms in the past week and has been extensively used in people with cancer. Scores range from 0-21 with below 7 indicating a non-case and the higher the score indicates greater symptom severity.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
Hospital Anxiety and Depression Scale (HADS)
Baseline depression
|
7.90 score on a scale
Standard Deviation 2.88
|
6.39 score on a scale
Standard Deviation 3.72
|
|
Hospital Anxiety and Depression Scale (HADS)
4 weeks depression
|
4.45 score on a scale
Standard Deviation 3.48
|
4.63 score on a scale
Standard Deviation 3.65
|
|
Hospital Anxiety and Depression Scale (HADS)
8 weeks depression
|
3.14 score on a scale
Standard Deviation 3.29
|
3.09 score on a scale
Standard Deviation 3.14
|
|
Hospital Anxiety and Depression Scale (HADS)
3 month follow-up depression
|
3.57 score on a scale
Standard Deviation 2.88
|
5.90 score on a scale
Standard Deviation 2.36
|
|
Hospital Anxiety and Depression Scale (HADS)
6 month follow-up depression
|
4.24 score on a scale
Standard Deviation 3.52
|
3.30 score on a scale
Standard Deviation 2.99
|
|
Hospital Anxiety and Depression Scale (HADS)
Baseline anxiety
|
9.33 score on a scale
Standard Deviation 3.48
|
8.70 score on a scale
Standard Deviation 4.24
|
|
Hospital Anxiety and Depression Scale (HADS)
4 weeks anxiety
|
6.88 score on a scale
Standard Deviation 3.25
|
7.97 score on a scale
Standard Deviation 3.78
|
|
Hospital Anxiety and Depression Scale (HADS)
8 weeks anxiety
|
5.89 score on a scale
Standard Deviation 3.31
|
7.08 score on a scale
Standard Deviation 4.47
|
|
Hospital Anxiety and Depression Scale (HADS)
3 month follow-up anxiety
|
6.04 score on a scale
Standard Deviation 3.79
|
5.97 score on a scale
Standard Deviation 4.41
|
|
Hospital Anxiety and Depression Scale (HADS)
6 month follow-up anxiety
|
6.18 score on a scale
Standard Deviation 4.33
|
5.67 score on a scale
Standard Deviation 3.82
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
Fatigue will be measured using the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), which is a 30 item self-report measure comprised of five subscales (general, emotional, physical, mental, vigor) and a total fatigue score. Each subscale score ranges from 0 to 24. The Total MSFI-SF score is calculated by adding the general, physical, emotional and mental subscale scores and subtracting vigor subscale score. Total MFSI-SF score ranges from -24 to 96 with a higher score indicating higher levels of cancer-related fatigue experienced by the patient.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
Baseline
|
29.57 score on a scale
Standard Deviation 16.75
|
26.64 score on a scale
Standard Deviation 19.38
|
|
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
4 weeks
|
16.52 score on a scale
Standard Deviation 17.50
|
17.17 score on a scale
Standard Deviation 20.49
|
|
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
8 weeks
|
4.72 score on a scale
Standard Deviation 16.17
|
6.05 score on a scale
Standard Deviation 19.62
|
|
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
3 month follow-up
|
9.13 score on a scale
Standard Deviation 16.44
|
6.79 score on a scale
Standard Deviation 18.41
|
|
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
6 month follow-up
|
10.04 score on a scale
Standard Deviation 18.13
|
5.95 score on a scale
Standard Deviation 17.65
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
The Hopkins Verbal Learning Test-Revised (HVLT-R) is a brief assessment of verbal learning and memory (immediate recall, delayed recall, delayed recognition). When scoring the HVLT-R, the three learning trials are combined to calculate a total recall score; the delayed recall trial creates the delayed recall score; the retention (%) score is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. These scores are then converted to an age-based T score (Mean=50, SD=10). Higher scores represent better verbal learning and memory.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
The Hopkins Verbal Learning Test-Revised (HVLT-R)
Baseline
|
49.84 t score
Standard Deviation 10.72
|
49.22 t score
Standard Deviation 12.64
|
|
The Hopkins Verbal Learning Test-Revised (HVLT-R)
8 weeks
|
49.11 t score
Standard Deviation 11.63
|
50.19 t score
Standard Deviation 10.95
|
|
The Hopkins Verbal Learning Test-Revised (HVLT-R)
3 month follow-up
|
54.25 t score
Standard Deviation 9.66
|
53.36 t score
Standard Deviation 11.47
|
|
The Hopkins Verbal Learning Test-Revised (HVLT-R)
6 month follow-up
|
55.94 t score
Standard Deviation 10.67
|
54.54 t score
Standard Deviation 10.94
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
The COWAT is a measure of verbal fluency, cognitive and motor speed, cognitive flexibility, strategy utilization, suppression of interference, and response inhibition. The total score is the total number of different words produced for all three letters in a timeframe of 3 minutes (1 minute for each letter). The scores are adjusted based on age and education level. A greater score indicates better verbal fluency. A score less then 33 indicates below average performance, scores between 34 and 45 indicate average performance, and scores greater than 45 are above average, with scores greater than 52 indicate superior performance. A minimum score is 0 (no words produced) and there is no set maximum score, as it depends on how many words can be produced in the given time frame.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
The Controlled Oral Word Association Test (COWAT)
Baseline
|
47.14 adj score on a scale
Standard Deviation 11.48
|
44.41 adj score on a scale
Standard Deviation 12.31
|
|
The Controlled Oral Word Association Test (COWAT)
3 month follow-up
|
51.04 adj score on a scale
Standard Deviation 12.91
|
48.42 adj score on a scale
Standard Deviation 12.20
|
|
The Controlled Oral Word Association Test (COWAT)
8 weeks
|
46.77 adj score on a scale
Standard Deviation 11.12
|
47.50 adj score on a scale
Standard Deviation 13.61
|
|
The Controlled Oral Word Association Test (COWAT)
6 month follow-up
|
50.02 adj score on a scale
Standard Deviation 11.44
|
49.62 adj score on a scale
Standard Deviation 13.87
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scale (WMS). Part A of digit span (the forward span) captures attention efficiency and capacity, and part B (the backward span) is an executive task dependent on working memory. The Digit Span subtest will be scored as one summary value. The unit of measure is the total recall. Scores on this measure range from 0-48, where greater scores indicates greater attention efficiency, capacity and working memory.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
The Digit Span
Baseline
|
28.49 score on a scale
Standard Deviation 4.06
|
28.44 score on a scale
Standard Deviation 5.03
|
|
The Digit Span
8 weeks
|
30.11 score on a scale
Standard Deviation 4.82
|
27.97 score on a scale
Standard Deviation 5.15
|
|
The Digit Span
3 month follow-up
|
30.73 score on a scale
Standard Deviation 4.97
|
28.17 score on a scale
Standard Deviation 6.14
|
|
The Digit Span
6 month follow-up
|
31.13 score on a scale
Standard Deviation 4.38
|
28.38 score on a scale
Standard Deviation 5.72
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) is composed of 75 items within nine non-overlapping theoretically and empirically derived clinical scales. It has 2 broad indexes (Behavioural Regulation and Metacognition), an overall summary score, and three validity scales. This analysis examines the overall summary score. T scores (M = 50, SD = 10; transformations of the raw scale scores) are used to interpret the individual's level of executive functioning. Traditionally, T scores at or above 65 are considered clinically significant. Greater scores indicate greater deficits in executive functioning.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)
Baseline
|
60.37 t score
Standard Deviation 10.31
|
59.13 t score
Standard Deviation 11.28
|
|
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)
8 weeks
|
51.14 t score
Standard Deviation 10.72
|
52.41 t score
Standard Deviation 11.30
|
|
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)
3 month follow-up
|
50.13 t score
Standard Deviation 10.67
|
51.54 t score
Standard Deviation 11.08
|
|
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)
6 month follow-up
|
50.65 t score
Standard Deviation 10.39
|
52.54 t score
Standard Deviation 13.60
|
SECONDARY outcome
Timeframe: Change from Baseline to Week 8, 3 month follow up, 6 month follow upPopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
The WPAI questionnaire was developed for the purpose of collecting productivity loss data within clinical trials and is suitable for direct translation into a monetary figure. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
The Work Productivity and Activity Impairment (WPAI)
3 month follow-up
|
6.25 percentage of work productivity loss
Standard Deviation 20.14
|
5.85 percentage of work productivity loss
Standard Deviation 20.37
|
|
The Work Productivity and Activity Impairment (WPAI)
Baseline
|
23.33 percentage of work productivity loss
Standard Deviation 34.04
|
18.28 percentage of work productivity loss
Standard Deviation 31.29
|
|
The Work Productivity and Activity Impairment (WPAI)
8 weeks
|
7.42 percentage of work productivity loss
Standard Deviation 21.48
|
11.54 percentage of work productivity loss
Standard Deviation 28.05
|
|
The Work Productivity and Activity Impairment (WPAI)
6 month follow-up
|
5.77 percentage of work productivity loss
Standard Deviation 19.36
|
5.63 percentage of work productivity loss
Standard Deviation 19.92
|
SECONDARY outcome
Timeframe: BaselinePopulation: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.
The Credibility/Expectancy Questionnaire (CEQ) is a 6-item questionnaire that captures both credibility beliefs and outcome expectancy. Questions on this scale are rated on a 1-to-9 point or 0-100% Likert scale, depending on the exact question. The scale was adapted to separately assess: (1) credibility beliefs for insomnia; (2) credibility beliefs for PCI; (3) expectancy beliefs for insomnia; and (4) expectancy beliefs for PCI. Since the CEQ utilizes two scales during the administration (1-9, and 0-100%), a composite score was derived for each factor (expectancy and credibility) by first standardizing the individual items and then summing those items for each factor yielding total scores, where higher values indicate stronger credibility and expectancy beliefs. Credibility beliefs scores ranged from 0 to 23 and expectancy beliefs scores ranged from 0 to 27.
Outcome measures
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
Credibility/Expectancy Questionnaire (CEQ)
Baseline credibility
|
15.37 scores on a scale
Standard Deviation 4.42
|
16.43 scores on a scale
Standard Deviation 3.94
|
|
Credibility/Expectancy Questionnaire (CEQ)
Baseline expectancy
|
19.68 scores on a scale
Standard Deviation 4.48
|
20.28 scores on a scale
Standard Deviation 4.19
|
Adverse Events
Cognitive Behaviour Therapy for Insomnia (CBT-I)
Waitlist Control Group
Serious adverse events
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 participants at risk
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 participants at risk
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
General disorders
Infection
|
1.6%
1/63 • Number of events 1 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
|
1.4%
1/69 • Number of events 1 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
|
|
General disorders
Surgery
|
1.6%
1/63 • Number of events 1 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
|
1.4%
1/69 • Number of events 1 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
|
Other adverse events
| Measure |
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 participants at risk
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
Waitlist Control Group
n=69 participants at risk
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period.
Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
|
|---|---|---|
|
General disorders
Headache or Migraine
|
6.3%
4/63 • Number of events 4 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
|
2.9%
2/69 • Number of events 2 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
|
|
General disorders
Increased Pain
|
7.9%
5/63 • Number of events 5 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
|
10.1%
7/69 • Number of events 7 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
|
|
General disorders
Fatigue
|
4.8%
3/63 • Number of events 3 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
|
7.2%
5/69 • Number of events 5 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
|
Additional Information
Dr. Sheila Garland
Memorial University of Newfoundland
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place